MOLECULAR PROFILING IN LOW-GRADE EC 51 3 cohort including age, tumor grade, FIGO stage, lymphovascular space invasion (LVSI), and the molecular subgroups showed that only high-grade EC, TP53-mutant, and advancedstage (FIGO III-IV) were independently associated with reduced DSS (respectively, HR 4.29 (95%-CI 2.15-8.53) P<.001, HR 1.76 (1.04-2.95) P=.03, HR 4.26 (2.50-7.26) P<.001). Conclusions and relevance Patients with low-grade EC have an excellent prognosis independent of molecular subgroup. Current data do not support routine molecular profiling in patients with low-grade EC, and demonstrate the importance of primary diagnostic tumor grading and selective profiling in low-grade EC to increase cost-effectiveness.
RkJQdWJsaXNoZXIy MTk4NDMw